AI
VERV

Accredited Investors’s Verve Therapeutics VERV Stock Holding History

Accredited Investors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$91.4K – 256
2025
Q1 		$91.4K Hold
20,000
– – 0.01% 231
2024
Q4 		$113K Hold
20,000
– – 0.01% 223
2024
Q3 		$96.8K Buy
20,000
+2,500
+14% +$14.5K 0.01% 230
2024
Q2 		$85.4K Buy
17,500
+2,455
+16% +$15.4K 0.01% 216
2024
Q1 		$200K Buy
+15,045
New +$200K 0.01% 203

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Accredited Investors's VERV Position: Q2 2025 in Review

Accredited Investors sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 20,000 shares — an estimated $91.4K sold.

Accredited Investors first reported a position in VERV in Q1 2024 and held it in 5 quarters. The position peaked at $200K in Q1 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Accredited Investors reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Accredited Investors sold 20,000 Verve Therapeutics shares in Q2 2025, an estimated $91.4K.
  • Accredited Investors first reported a position in Verve Therapeutics in Q1 2024 and held it in 5 quarters.
  • Accredited Investors's Verve Therapeutics position peaked at $200K in Q1 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Accredited Investors's 13F filing for Q2 2025, filed 8 Aug 2025.